Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of 9MW2821 in Advanced Solid Tumors
NCT05216965Phase 2Recruiting
- Sponsor
- Mabwell
- Start
- Jun 2022
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bulumtatug fuvedotin in solid tumor, sponsored by Mabwell. Primary endpoints: Incidence of adverse events and Objective Response Rate up to 24 months. Started Jun 2022; status: recruiting.
02
Drugs
bulumtatug fuvedotin
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05216965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05216965.